🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Consumer Staples Sector SEC Filings — April 21, 2026

Across 50 SEC filings from diverse sectors (despite Consumer Staples focus, dominated by industrials, financials, REITs, and biotechs), Q1 2026 results show robust revenue growth averaging +15-25% YoY in reporting companies like GE Aerospace (+25%), Zurn Elkay (+11%), and Valmont (+6%), but margin compression in 4/7 key earners (e.g., GE -490 bps GAAP, Aerospace -230 bps). Capital allocation remains shareholder-friendly with dividends (Delek $0.255/share, Armour $0.24/share, Valmont +13% to $0.77) and buybacks (Zurn $50M, Donnelley $150M new program, Valmont $57.5M Q1). Positive M&A/licensing (NEXGEL triples revenue pro-forma to $35M) and financings (Prelude $90M raise) offset risks like operational disruptions (Aspen explosion) and partnership terminations (Rigel with Lilly). Forward guidance largely maintained or raised (GE full-year EPS $7.10-$7.40, Valmont $21.50-$23.50, Zurn Q2 8-9% growth), signaling resilience; institutional 13Fs (e.g., Pinnacle, Morton Brown) show heavy tech/ETF tilts with no major shifts. Proxy-heavy filings highlight governance refreshes and compensation approvals, with mixed sentiment (25% positive, 30% mixed, 45% neutral). Portfolio-level: 6/10 key filers grew EPS YoY, but 3 saw loan/asset declines; watch Q1 earnings catalysts Apr 22-25 for guidance updates amid tariff risks.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 21, 2026

Across 50 filings in the USA S&P 500 Industrials stream (April 21, 2026), dominant themes include robust revenue growth in defense and aerospace (e.g., GE +25% YoY, RTX +9% YoY organic, Northrop +4% YoY) offset by margin compression (GE profit margin -490 bps, RTX segment mix issues), mixed bank earnings irrelevant to core industrials but showing NIM expansion (Peoples 4.16%, United 3.65% +29 bps YoY), and heightened SPAC/M&A activity in adjacent tech/housing (Boxabl merger, Forge Nano $1.2B deal). Period-over-period trends reveal 7/10 key industrials with YoY revenue growth averaging +15% but operating margins down avg -150 bps due to costs/tariffs; capital returns strong with buybacks (Tractor Supply $118M) and dividends (Delek $0.255/share). Forward guidance largely reaffirmed or raised (RTX EPS to $6.70-6.90, Danaher to $8.35-8.55), signaling conviction amid sector rotation. 13F filings (20+) show heavy industrials exposure (e.g., Caterpillar top in Independent Wealth $18.5M, Generali Freeport-McMoRan $52M), indicating institutional accumulation. SPAC resurgences in quantum/housing flag construction/aerospace adjacency opportunities, while pharma filings (Tarsier IPO, Genprex trials) suggest biotech crossover. Overall, bullish on defense backlog growth ($95B Northrop) but cautious on industrial cost pressures; actionable now: overweight RTX/GE pre-guidance catalysts.

12 high priority 38 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 21, 2026

Across the 8 filings in the USA S&P 500 Energy intelligence stream, core Energy players like Halliburton and Devon Energy show mixed performance: Halliburton doubled Q1 2026 net income YoY to $461M despite flat $5.4B revenue and segment declines, while Devon exceeded 2025 FCF ($2.56B vs $2.5B target) and production targets (840 MBOE/d vs 823) but posted -13% YoY FCF decline amid a pending Coterra merger. Institutional 13F filings from Williams & Novak and Stokes Capital reveal neutral, diversified portfolios heavy in ETFs with minimal Energy exposure. Non-Energy filings highlight growth in Interactive Brokers (17% YoY revenue to $1.67B), a SPAC IPO by Hall Chadwick aiming for $265M raise, positive board addition at Howard Hughes, and neutral severance tweaks at Robert Half. Overarching themes include resilient profitability in Energy services amid flat revenues, M&A catalysts like Devon's Feb 1, 2026 Coterra deal, steady capital returns (Halliburton $100M buybacks + $142M dividends), and neutral institutional conviction. Portfolio-level trends show international offset for North America weakness in Energy (Halliburton Int'l +3% vs NA -4%), signaling sector rotation opportunities. Critical implications: Monitor Energy M&A and Q2 catalysts for alpha amid geopolitical drags.

3 high priority 5 medium 8 total filings
· daily

US Material Events SEC 8-K Filings — April 21, 2026

Across 50 8-K filings from April 21, 2026, M&A activity dominates with 12+ deals totaling $3B+ in value, spanning AI (SoundHound-LivePerson $250M EV), industrials (Brady-Honeywell PSS $1.4B), and biotech (NEXGEL-Celularity tripling rev to $35M pro forma), signaling aggressive expansion amid positive sentiment in 70% of filings. Leadership churn affects 25+ companies with 15 appointments/promotions (e.g., Delek EVPs, Abacus CAO/CIO) vs 20 retirements/resignations (e.g., Voyager CFO, Rayonier CEO), mostly neutral but mixed in strategic pivots like Rayonier review. Financings surge with $250M+ raised via equity/debt (Prelude $90M, Surf Air $15M, Goldman Sachs $750M notes), while capital raises fund growth without major dividend/buyback shifts. Where PoP data available, revenue trends strong (CrowdStrike FY24 $3.06B to FY26 $4.81B +57%; NHI 2025 $39.7M lease rev lost post-sale), but outliers like Rigel collab termination flag risks. Portfolio-level: Small/mid-cap biotech/tech lead bullish catalysts (H2 2026 closes), deleveraging via asset sales (NHI $560M proceeds, 2.3x net D/E), no broad margin compression but unverified metrics in mining (Sow Good). Implications: Buy M&A targets/acquirers pre-close, monitor exec turnover for conviction, H2 catalysts could drive 10-20% sector pops.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 21, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream on April 21, 2026, dominant themes include heavy institutional accumulation in mega-cap tech stocks (Apple, Microsoft, NVIDIA, Alphabet) via 13F-HR disclosures from 16 managers totaling billions in AUM, signaling sustained conviction amid market rotations. Banking sector shows resilient YoY growth (e.g., United Community Banks +18% net income YoY, +12% revenue) but QoQ softness in income and rising provisions, with NIM expansions averaging +20 bps YoY. Healthcare mixed with UnitedHealth raising FY2026 adjusted EPS guidance to >$18.25 despite Optum dip, while tech/industrials highlight positive capital returns (AppLovin $2.2B buybacks, Delek dividend) and M&A (Onto Innovation $710M stake). SPAC IPO filings (AEI CapForce, Vernal, Collective, East West) indicate renewed blank-check activity with dilution risks and 18-24 month de-SPAC deadlines. Proxy statements cluster around June 2026 annual meetings, building a catalyst calendar. No widespread insider selling; instead, performance awards to execs (CrowdStrike, PPG) reflect alignment. Portfolio-level trends: 4/5 banks report YoY EPS growth averaging +15%, but 3 show QoQ net income declines; overall sentiment leans neutral-positive with mixed in financials.

17 high priority 33 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 21, 2026

The April 21, 2026, SEC filings reveal a surge in 13F-HR reports from 20+ institutions showcasing overwhelming conviction in mega-cap tech (Apple, NVDA, MSFT topping most portfolios) and broad ETFs, signaling portfolio-level bullishness on US equities amid market highs. Earnings releases show mixed financial/healthcare performance: Synchrony Financial +6% YoY net earnings with NIM stability and massive $6.5B buyback; UnitedHealth +2% YoY revenue, margin expansion, raised FY2026 EPS >$18.25; but Optum dip and First United loan stagnation highlight sector pressures. SPAC activity dominates with 10+ filings (e.g., Archimedes/Forge Nano $1.2B merger, Titan/Key Mining titanium project), pointing to M&A resurgence in tech/mining/quantum amid critical minerals demand. Capital returns accelerate (Synchrony 13% dividend hike, UNH $2B Q2 repurchase, News Corp $1B program), while risks emerge in consumer (Allbirds Q1 net loss $19.6M, gross margin 27.8%) and biotech (PAVmed going concern). Forward catalysts cluster in Q2: AGMs, SPAC closings, earnings calls. Overall, actionable alpha in SPACs/outliers like Onto Innovation's $710M Rigaku stake (accretive H2 2026) vs. deteriorating microcaps.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 21, 2026

Across 50 filings from the S&P 500 Consumer Discretionary stream, dominant themes include heavy institutional portfolio concentration in tech giants (AAPL, MSFT, NVDA across 25+ 13F-HRs totaling billions), mixed Q1 2026 financial performance in consumer-adjacent lenders with average NIM expansion of +25 bps YoY in 5 reporters (Hanmi +25bps QoQ, Northfield +38bps YoY) offset by NAV declines in BDCs (Onex -10% QoQ), and robust capital returns averaging $100M+ programs (Synchrony $6.5B buyback, Donnelley $150M). M&A activity persists with litigation risks (Farmer Bros 14 demands on Royal Cup merger) and SPAC dilutions (AEI CapForce NTBV $7.85 vs $10 IPO), while forward guidance holds steady amid macro pressures (Equifax FY revenue +10-12%). Portfolio-level trends show deposit growth in banks (+1.8% QoQ Hanmi, +8.4% ann. Northfield) but loan declines (-0.3% Hanmi, -5.1% ann. Northfield), signaling cautious lending. Consumer-facing signals mixed: Synchrony purchase volumes +6% YoY but charge-offs monitored monthly; furniture/retail exec departures (Bassett, Simply Good Foods). Implications favor dividend/buyback plays over growth, with catalysts in Q2 mergers/proxy votes.

8 high priority 42 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 21, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (with heavy financial services crossover), Q1 2026 results for reporting companies show average revenue growth of ~8% YoY (range 2-23%, e.g., UNH +2%, ISRG +23%, Danaher +3.7%, MSCI +14%), mixed margins (expansions in UHC +40bps, NIM Hanmi 3.38%; compressions Optum +140bps cost ratio), and resilient earnings (avg +10% YoY). Healthcare standouts include ISRG's 17% procedure growth and Danaher's 11.5% biotech surge, offsetting UNH Optum softness; biotech catalysts like Inhibrx's 20% ORR emerge positively. Capital allocation skews bullish with 8+ buyback/div announcements (Synchrony $6.5B no expiry, UNH $2B Q2, Danaher no Q1 buys vs $1.1B prior). 20+ 13F filings reveal institutional tilt to ETFs (avg 60%+ allocation) and mega-caps (Apple/Microsoft/NVDA ubiquitous), signaling defensive positioning. Guidance mostly raised (UNH FY EPS >$18.25, Danaher $8.35-8.55), but Prudential's sales suspension extension flags Japan risks. Portfolio trend: Regional banks outperforming mega (NIM +48bps YoY Bridgewater vs Cap One -39bps QoQ), healthcare devices/biotech > providers.

6 high priority 44 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 21, 2026

Across 50 DEF 14A proxy statements filed around April 21, 2026, for US SEC-listed companies, a dominant theme is preparation for clustered 2026 annual meetings primarily June 1-16, featuring routine director elections (pluarlity or majority votes), say-on-pay advisory votes, auditor ratifications, and equity incentive plan expansions/amendments in 20+ filings signaling potential dilution risks. Where 2025 financial data is enriched, period-over-period trends reveal stark bifurcation: 9 companies reported robust revenue growth (e.g., AppLovin +70% YoY, Ligand +48% royalties YoY, LendingClub +33% originations YoY) driving positive sentiment, while 2 showed deterioration (Mercer net loss expanded to $(498)M YoY, Cherry Hill BVPS returns negative early quarters with dividend cut from $0.15 to $0.10). Capital allocation highlights shareholder returns via buybacks (AppLovin $2.2B, +$3.2B authorization) and dividends (Power Integrations +2.4% increase), with M&A catalysts like Odyssey's AOM merger (close late Q2/early Q3 2026) and BioMarin's acquisitions. No widespread insider trading data, but leadership transitions (e.g., CEOs in Amerant, Power Integrations) signal governance evolution; portfolio-level, biotech/pharma (12/50) and tech/advertising show outperformance vs. finance/REITs with mixed trends. Implications: Bullish for growth outliers pre-AGM rallies, caution on dilution-heavy plans and weak performers amid neutral sentiment in 70% of filings.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 21, 2026

The IPO Pipeline stream shows a cluster of four high-materiality filings on April 21, 2026, dominated by three S-1 registrations (two SPACs and one operating company), signaling a potential resurgence in blank-check and tech IPO activity amid neutral sentiment across all. Hall Chadwick and East West Ave SPACs feature standard $10/unit structures with sponsor/private commitments totaling millions in warrants/units, while Fusemachines discloses stable YoY customer/supplier concentration risks from 2024-2025 periods. Tecnoglass S-4 proxy emphasizes operational risks ahead of its 2026 AGM for Florida reincorporation and JV benefits with Saint-Gobain. No significant period-over-period financial trends emerge due to pre-IPO nature, but redemption scenarios up to 100% in SPACs highlight dilution risks; sponsor purchases indicate management skin-in-the-game. Market implications include near-term IPO pricing catalysts and watch for SPAC de-SPAC timelines within 24 months, positioning investors for early access to fresh capital raises totaling at least $265M.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — April 21, 2026

The 50 filings reveal a surge in M&A and SPAC activity, with 15+ deals including SoundHound AI's $43M acquisition of LivePerson (22% premium, debt-free post-close), Brady Corp's $1.4B Honeywell PSS buy (8x EBITDA, double-digit EPS accretive), and multiple SPAC mergers like Archimedes/Forge Nano ($1.2B equity value) and Titan/Key Mining ($303M), signaling bullish consolidation in AI, tech, mining, and critical minerals amid $500M+ revenue opportunities. Period-over-period trends show mixed financial health: revenue growth in GE Aerospace (+25% YoY to $12.4B), Danaher (+3.7% to $5.95B), and CMB.TECH (+16% to $1.89B), but margin compressions (GE -490bps GAAP profit margin, Danaher comprehensive income -75%), rising expenses (CMB vessel ops +111%), and deteriorations like Black Hawk net income -79% YoY. Insolvency risks persist in Quadrant Televentures and Setubandhan Infrastructure (CIRP ongoing, plans rejected), alongside delisting threats (Quetta Acquisition). Capital allocation favors buybacks (Aurobindo ₹800Cr, 0.93% shares) and repurchases (AppLovin $2.2B), with positive insider alignment via CrowdStrike's 100K PSUs to President. Sector themes highlight SPAC resurgence in quantum/biotech/healthcare and resource pivots (Sow Good graphite). Portfolio implications: overweight M&A catalysts H2 2026, monitor SPAC redemptions/delays, avoid insolvency-exposed names.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 21, 2026

Across 21 Q1 2026 filings, revenue growth was a dominant theme with 16/21 companies reporting YoY increases averaging +16% (led by GE Aerospace +24.7%, Range Resources +50%, Aircastle +18.8%), though profitability was mixed: 12/21 saw net income growth (avg +35% where positive) but 6 experienced declines (avg -45%), driven by higher expenses and one-offs. Margin compression appeared in 8/21 (e.g., GE Aerospace 26.4% vs 28.7%, 3M EPS -40%), offset by operational leverage in defense (Northrop op income +73%) and leasing (Aircastle EBITDA +19.7%). Capital allocation leaned shareholder-friendly with buybacks in 7/21 (total ~$1.5B, e.g., MSCI $414.8M, Pegasystems $167M) and dividend hikes in 5 (e.g., Northrop $2.31 vs $2.06, Range $0.10 vs $0.09), but cash burns persisted in 9/21 amid acquisitions/investments. Sector strength in aerospace/defense (GE, Northrop, RTX, Aircastle) and water/industrials (Zurn +11.4% sales), contrasted by weakness in small-caps (Fly-E -53% rev, Pacific negative sentiment). Implications: Bullish for large-cap industrials/defense on growth/margins; caution on micro-caps with cash depletion; portfolio rotation toward buyback-heavy names like MSCI/Equifax for near-term returns.

21 high priority 21 total filings
· daily

US SEC Trading Suspension Halt Orders — April 21, 2026

Nine Nasdaq-listed small-cap companies disclosed deficiency notices on April 16-20, 2026, primarily for late Form 10-K filings (6/9 cases: Atlantic American, Allied Gaming, Driven Brands, Laser Photonics, Society Pass, Aimei Health), with others citing bid price violation (Expensify), annual meeting delay (Fly-E Group), and low stockholders' equity (ENDRA Life Sciences); no immediate trading suspensions but delisting risks escalate with clustered compliance deadlines in June-October 2026. Sentiment is negative across 8/9 filings (materiality 9/10 for most), reflecting broad micro-cap distress from accounting delays, administrative lapses, and financial weaknesses. Driven Brands provides the only substantive period-over-period data, showing FY2025 SSS growth of 3.5%-3.7% (Driven) and 6.1%-6.2% (Take 5) vs flat Q4, revenue $1,850-$1,860M (stable YoY implied), Adjusted EBITDA $440-$450M (lower due to restatement), and net debt reduction 24% QoQ to $1.6B with net unit growth of 175 FY2025/29 Q1 2026. Laser Photonics stands out as resolved swiftly (10-K filed, matter closed April 21), while others plan filings/compliance by mid-June. Portfolio-level pattern: 67% tied to reporting failures, signaling sector-wide governance/audit issues; investors face heightened volatility from reverse splits, appeals, and potential OTC transfers. Key implication: Short-term shorts on unresolved names, watch for compliance bounces.

9 high priority 9 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 21, 2026

Across 45 filings in the USA Corporate Distress & Bankruptcy stream (33 new), small-cap distress dominates with 12 companies (e.g., Expensify, Atlantic American, Fly-E Group, Allied Gaming, Society Pass, ENDRA Life Sciences, Aimei Health) receiving Nasdaq deficiency notices for late 10-Ks, low bid prices (<$1), low equity (<$2.5M), or missed shareholder meetings, signaling widespread compliance risks and potential delistings by Q3/Q4 2026. Positive offsets include accretive M&A (SoundHound AI acquiring LivePerson at 22% premium for $500M rev opportunity; Brady acquiring Honeywell PSS at 8x EBITDA, double-digit EPS accretive; NHI divestiture deleveraging to 2.3x net debt/EBITDA) and financings ($90M Prelude Therapeutics offering, $15M Surf Air), but debt restructurings (Reborn Coffee forbearance, NKGen $40M consolidated note) highlight liquidity strains. Limited period data shows mixed trends: Driven Brands Q4 SSS flat (0.3-0.5%) vs FY +3.5-3.7%, Take 5 SSS Q4 +1% vs FY +6.2%; NHI loses $39.7M 2025 lease rev from divestiture. No insider selling clusters, but sparse activity (e.g., Howard Hughes director investing $10M warrants); forward guidance flags H2 2026 catalysts like deal closes (SOUN/LPSN, Onto/Rigaku 27% stake). Portfolio implication: Small-cap consolidation via M&A amid delisting pressures, favor deleveraging plays over compliance laggards.

45 high priority 45 total filings
· daily

US Executive Officer Management Changes SEC — April 21, 2026

Across 32 SEC filings on US executive and director changes dated April 21, 2026, the dominant theme is orderly leadership transitions, with 18 planned retirements/non-re-elections (e.g., CAVA, Radian, Xeris, CION, Trulieve, SandRidge) signaling proactive succession amid neutral sentiment, contrasted by 10 positive appointments/promotions (Delek, Abacus, Envoy, MGE Energy) bringing deep industry expertise. Limited period-over-period financials highlight CrowdStrike's exceptional growth (revenue +57% from $3.06B FY2024 to $4.81B FY2026, ARR +52% to $5.25B, 300% stock return in 95th percentile of S&P 500), while others show capital allocation via equity awards (CrowdStrike 100k PSUs targeting $20B ARR by ~2030, PPG $1.5M MSUs, MGE 25k RSUs) and Adobe's $25B buyback through 2030. Negative outliers include CTO termination at Airgain, chairman resignation over strategy at Lipocine (mixed sentiment), board death at Enigma-Bulwark, and key departures at Masco/Voyager/Timken without immediate successors. Portfolio-level patterns reveal strong AGM support (HP 73.6M-share plan approved, PPG/Warrior unanimous), biotech leadership refreshes (Sagimet/Voyager CMO/CFO shifts), and severance enhancements (Virgin Galactic, Cerus, Robert Half amendments), implying management alignment but watch for execution risks. Market implications favor stability in tech/biotech with growth catalysts, caution in industrials/energy on leadership gaps.

32 high priority 32 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 21, 2026

Across 32 filings on USA board room changes from April 21, 2026, overarching themes include 18 neutral departures/retirements (mostly not due to disagreements), 8 positive appointments/promotions of experienced executives, 3 negative events (death, termination, separation), and supportive annual meeting outcomes with equity plan approvals. Period-over-period trends highlight CrowdStrike's exceptional revenue growth (FY2024 $3.06B to FY2026 $4.81B, +57%; ARR $3.44B to $5.25B, +53%) and 300% stock return (95th percentile S&P 500), contrasting with limited financial deterioration elsewhere; capital allocation favors equity incentives (e.g., Adobe's $25B buyback through 2030, PPG MSUs). Critical developments: Experienced hires in refining (Delek), medtech (Envoy), and promotions (Abacus, MGE) signal continuity; insider-aligned awards (CrowdStrike PSUs to 2028) build long-term conviction. Portfolio-level patterns show sector dispersion—energy/industrials stable, biotech high turnover (5/7 neutral/mixed), tech positive incentives—implying opportunities in leadership-stabilized firms amid M&A expansions.

32 high priority 32 total filings
· daily

US Merger & Acquisition SEC Filings — April 21, 2026

The 13 filings reveal a bifurcated US M&A landscape dominated by SPAC activity (9/13 filings), with fresh IPOs from JATT II ($60M healthcare-focused), APEX Tech (over-allotment full exercise adding $3M), and Maywood 2 ($100M) signaling renewed investor appetite amid no prior period comparisons indicating baseline launches, contrasted by distress in aging SPACs like PHP Ventures (extension contributions cut ~80% from $4,771 to $957/month), Pyrophyte (third extension deposits), Charlton Aria, and Quetta (delisting risks). Operating company M&A highlights include NEXGEL's accretive Celularity acquisition tripling pro-forma annual revenue to $35M with immediate profitability boost and three 510(k) filings planned 2026-2028, XMax's $5.45M investment yielding >99.9% stake in SpaceX-holding fund, and CVB Financial's merger with Heritage scaling assets >$20B, loans ~$12B, deposits ~$17B to become a top-10 California bank holding company. No broad insider trading or dividend/buyback trends reported across filings, but capital locked in SPAC trusts (~$100M+ each for new IPOs) underscores dry powder for future deals; sentiment skews positive (7/13) with high materiality deals (avg 7.7/10). Portfolio-level pattern: SPAC extensions/delays average 3-4 months YoY without business combinations, flagging sector fatigue, while banking consolidation offers scale-driven outperformance. Forward catalysts cluster in late April-May 2026, prioritizing M&A execution over SPAC launches.

13 high priority 13 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 21, 2026

Overnight SEC filings reveal heightened SPAC activity with multiple merger announcements and IPOs in tech, mining, quantum computing, and biotech sectors, signaling robust M&A appetite amid critical minerals demand and AI tailwinds. Earnings and operational updates show mixed results: healthcare giant UnitedHealth Group raised FY2026 adjusted EPS guidance to >$18.25 despite Optum dip, Synchrony Financial posted 6% YoY net earnings growth with new $6.5B buyback, while Allbirds reported Q1 net loss of $19.6M on 27.8% gross margins. Period-over-period trends indicate financials resilient (e.g., NIM expansion at First United to 3.83%, charge-offs down 96 bps at Synchrony), but loan stagnation and covenant waivers flag banking stress. 24 of 50 filings are 13F-HR disclosures dominated by tech giants (Apple, NVDA, MSFT) and ETFs, reflecting institutional conviction in growth equities. Capital allocation leans bullish with buybacks/div hikes (Synchrony 13% div increase, UNH $2B repurchase), but shelf registrations (PAVmed, Battalion Oil) highlight dilution risks. Portfolio-level patterns show 70%+ of 13F value in tech/ETFs, positioning for AI/semicon rally; watch Q2 catalysts like annual meetings and SPAC closings for alpha.

15 high priority 35 medium 50 total filings
· daily

Biotech Small-Cap Approvals — April 20, 2026

The FDA approved 8 Other (FALLBACK) category products between April 20 and April 20, 2026, with a mix of 0 NMEs, 0 biosimilars, and 0 label expansions, all generating neutral investment signals of medium strength and materiality. These approvals involve diverse small molecule products across sponsors like TEVA PHARMS INC, AUROBINDO PHARMA LTD, and BAXTER HLTHCARE CORP, including GLYCEROL PHENYLBUTYRATE, METHOTREXATE SODIUM, and DEXMEDETOMIDINE HYDROCHLORIDE. No dominant therapeutic area theme or clustering is evident from the data. The highest-conviction signal is TEVA PHARMS INC's neutral approval for GLYCEROL PHENYLBUTYRATE, implying modest portfolio diversification upside for the sponsor amid NOT_DISCLOSED commercial details. Key risk/watch item: absence of peak sales, exclusivity, and pricing data necessitates monitoring post-launch performance and competitive uptake.

8 total filings
· daily

Big Pharma Approvals — April 20, 2026

This period featured 3 'Other' approvals (0 NMEs, 0 biosimilars, 0 label expansions), all classified as bullish label expansions for big pharma stalwarts GENENTECH INC's INAVOLISIB (ITOVEBI), ASTRAZENECA AB's EPLONTERSEN SODIUM (WAINUA Autoinjector), and JANSSEN BIOTECH's USTEKINUMAB (STELARA). No dominant therapeutic area theme emerges, with approvals spanning diverse indications. Highest-conviction signal is JANSSEN BIOTECH's USTEKINUMAB label expansion, extending STELARA's immunology franchise reach and supporting revenue defensiveness amid patent cliffs. All signals carry moderate strength (5/10) and materiality (5/10), highlighting steady lifecycle management execution. Key risk/watch item: NOT_DISCLOSED commercial details (peak sales, exclusivity, pricing) necessitate monitoring post-approval uptake and competitive encroachment.

3 total filings